Companies Dominating the Histiocytosis Treatment Market
- Swedish Orphan Biovitrum AB
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AB2 Bio Ltd.
- Alpine Immune Sciences.
- Bellicum Phamaceuticals, Inc.
- Xencor
- TG Therapeutics, Inc.
- Affimed GmbH
- F. Hoffmann-La Roche Ltd
- Mereo Biopharma Group PLC
- Innovent
Browse Key Market Insights with Data Illustration:
In the News
- For the treatment of adult patients with histiocytic neoplasms, such as Langerhans cell histiocytosis, Rosai-Dorfman disease, and Erdheim-Chester disease, the FDA has approved cobimetinib (Cotellic).
- Dabrafenib (Tafinlar) and trametinib (Mekinist), two targeted medications, were recently approved by the Food and Drug Administration (FDA) for the treatment of almost any kind of advanced solid tumour with a certain mutation in the BRAF gene.
